STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Clinical trials for STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo tackles resistant lung cancer in early trial
Disease control OngoingThis early-phase study tests a new two-drug combination (sapanisertib plus osimertinib) in about 36 people with advanced EGFR-mutant non-small cell lung cancer that has worsened after standard treatment. The main goal is to find the safest dose and understand side effects. The ap…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
New drug cocktail shows promise against tough cancers
Disease control OngoingThis study tested a combination of two drugs, cediranib and olaparib, in 122 people with advanced or spreading solid tumors, including certain breast, lung, and pancreatic cancers. The goal was to see if the combo could shrink tumors by blocking enzymes that help cancer grow and …
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC